| pubmed-article:19066607 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0280098 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0078257 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19066607 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:19066607 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19066607 | pubmed:dateCreated | 2009-1-7 | lld:pubmed |
| pubmed-article:19066607 | pubmed:abstractText | Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >or=2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of >or=8 months (3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% (95% CI 28-58%) in arm B, respectively. The median overall survival, 1-year survival -rate and response rate of patients treated in arm A was 11.0 months, 38, and 23.8%, arm B 7.0 months, 29, and 20%. In conclusion, the paclitaxel/carboplatin regimen showed clinically meaningful activity in this randomised trial (Clinical trial registration number 219, 'Deutsches KrebsStudienRegister', German Cancer Society.) | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19066607 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19066607 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19066607 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19066607 | pubmed:issn | 1532-1827 | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:HoffmannMM | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:LindAA | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:MengelJJ | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:BernhardHH | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:StahlMM | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:JahnAA | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:KretzschmarAA | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:KaiserUU | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:KullmannFF | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:SteinbachSS | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:BurkardSS | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:OtrembaBB | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:HuebnerGG | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:FolprechtGG | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:SchoffskiPP | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:Al-BatranS... | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:KohneC HCH | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:AldaoudAA | lld:pubmed |
| pubmed-article:19066607 | pubmed:author | pubmed-author:German CUP... | lld:pubmed |
| pubmed-article:19066607 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19066607 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:19066607 | pubmed:volume | 100 | lld:pubmed |
| pubmed-article:19066607 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19066607 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19066607 | pubmed:pagination | 44-9 | lld:pubmed |
| pubmed-article:19066607 | pubmed:dateRevised | 2010-9-22 | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:meshHeading | pubmed-meshheading:19066607... | lld:pubmed |
| pubmed-article:19066607 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19066607 | pubmed:articleTitle | Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. | lld:pubmed |
| pubmed-article:19066607 | pubmed:affiliation | Westpfalz-Klinikum, Hellmut-Hartert-Str 1, 67655 Kaiserslautern, Germany. lghuebner@web.de | lld:pubmed |
| pubmed-article:19066607 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19066607 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19066607 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
